Chapter 16. Breast Cancer
Select the agent that is administered via intramuscular (IM) injection for the treatment of metastatic estrogen receptor-positive breast cancer.
Answer d is correct. Faslodex is administered by IM injection to women with estrogen receptor (ER)+ metastatic breast cancer.
Answer a in incorrect. Anastrozole is administered orally to patients with ER+ metastatic breast cancer.
Answer b is incorrect. Avastin is administered intravenously to patients with breast cancer.
Answer c is incorrect. Herceptin is administered intravenously to patients with breast cancer characterized by an overexpression of human epidermal growth factor receptor-2 (HER-2).
Which of the following conditions would be a contraindication to administration of tamoxifen for the prevention of breast cancer in a “high risk” premenopausal patient?
a. History of deep venous thrombosis.
b. First-degree relative with estrogen receptor (ER)-negative breast cancer.
c. History of diabetes mellitus.
Answer a is correct. Tamoxifen is associated with an increased risk for developing thromboembolic events. Administration of tamoxifen to prevent breast cancer is contraindicated in patients with a history of deep venous thrombosis or pulmonary emboli.
Answer b is incorrect. The ER status of first-degree relatives is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.
Answer c is incorrect. Diabetes mellitus is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.
Answer d is incorrect. A history of seizures is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.
A premenopausal woman with estrogen receptor-negative, node-positive breast cancer is starting doxorubicin and cyclophosphamide adjuvant treatment. What would you recommend to determine the severity of the most common toxicity associated with this treatment regimen?
b. A complete blood count including platelets 1 week after administration of the chemotherapy.
c. Serum bilirubin and aspartate transaminase.
Answer b is correct. Myelosuppression (neutropenia, thrombocytopenia) is the most common treatment-related adverse effect associated with this adjuvant treatment regimen. Nearly 100% of patients receiving this treatment regimen will experience myelosuppression.
Answer a is incorrect. Although ...